Biomedical Engineering Reference
In-Depth Information
antibodies that combine cell targeting and antibody-catalyzed
prodrug activation. Proc. Natl. Acad. Sci. USA 104, 5584-
5589.
21. Tietze LF, Schmuck K, Schuster HJ, Muller M, Schuberth, I.
(2000) Synthesis and biological evaluation of prodrugs based
on the natural antibiotic duocarmycin for use in ADEPT and
PMT. Chemistry 17, 1922-1929.
22. Frei E, 3rd, Teicher BA, Holden SA, Cathcart KN, Wang YY.
(1988) Preclinical studies and clinical correlation of the effect
of alkylating dose. Cancer Res. 48, 6417-6423.
23. Kuefner U, Lohrmann U, Montejano YD, Vitols KS, Huen-
nekens FM. (1989) Carboxypeptidase-mediated release of
methotrexate from methotrexate alpha-peptides. Biochemistry
28, 2288-2297.
24. Kerr DE, Li Z, Siemers NO, Senter PD, Vrudhula VM. (1998)
Development andactivities of anewmelphalanprodrugdesigned
for tumor-selective activation. Bioconjug. Chem. 9, 255-259.
25. Springer CJ, Antoniw P, Bagshawe KD, Searle F, Bisset GM,
Jarman M. (1990) Novel prodrugs which are activated to
cytotoxic alkylating agents by carboxypeptidase G2. J. Med.
Chem. 33, 677-681.
26. Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA,
Antoniw P, et al. (1991) Ablation of human choriocarcinoma
xenografts in nude mice by antibody-directed enzyme prodrug
therapy (ADEPT) with three novel compounds. Eur. J. Cancer
27, 1361-1366.
27. Sharma SK, Bagshawe KD, Burke PJ, Boden RW, Rogers GT.
(1990) Inactivation and clearance of an anti-CEA carboxy-
peptidase G2 conjugate in blood after localisation in a xeno-
graft model. Br. J. Cancer 61, 659-662.
28. Sharma SK, Bagshawe KD, Springer CJ, Burke PJ, Rogers GT,
Boden JA, et al. (1991) Antibody directed enzyme
prodrug therapy (ADEPT): a three phase system. Dis. Markers
9, 225-231.
29. Sharma SK, Boden JA, Springer CJ, Burke PJ, Bagshawe KD.
(1994) Antibody-directed enzyme prodrug therapy (ADEPT).
A three-phase study in ovarian tumor xenografts. Cell Biophys.
24-25, 219-228.
30. Melton RG, Boyle JM, Rogers GT, Burke P, Bagshawe KD,
Sherwood RF. (1993) Optimisation of small-scale coupling of
A5B7 monoclonal antibody to carboxypeptidase G2. J. Immu-
nol. Methods 158, 49-56.
31. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Boden JA,
Rogers GT, et al. (1991) Antibody directed enzyme prodrug
therapy (ADEPT): clinical report. Dis. Markers 9, 233-238.
32. Bagshawe K.D, Begent R.H.J. (1996). First Clinical experi-
ence with ADEPT. Adv. Drug Deliv. Rev. 22, 365-367.
33. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P. (1995)
Antibody-directed enzyme prodrug therapy: A pilot scale
clinical trial. Tumor Targeting 1, 17-29.
34. Springer CJ, Poon GK, Sharma SK, Bagshawe KD. (1993)
Identification of prodrug, active drug, and metabolites in an
ADEPT clinical study. Cell Biophys. 22, 9-26.
35. Bagshawe KD, Sharma SK. (1996) Cyclosporine delays host
immune response to antibody enzyme conjugate in ADEPT.
Transplant Proc. 28, 3156-3158.
36. Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ,
Martin J, et al. (2000) Antibody-directed enzyme prodrug
therapy: efficacy and mechanism of action in colorectal carci-
noma. Clin. Cancer Res. 6, 765-772.
37. Martin J, Stribbling SM, Poon GK, Begent RH, Napier M,
Sharma SK, et al. (1997) Antibody-directed enzyme prodrug
therapy: pharmacokinetics and plasma levels of prodrug and
drug in a phase I clinical trial. Cancer Chemother. Pharmacol.
40, 189-201.
38. Springer CJ, Dowell R, Burke PJ, Hadley E, Davis DH, Blakey
DC, et al. (1995) Optimization of alkylating agent prodrugs
derived from phenol and aniline mustards: a new clinical
candidate prodrug (ZD2767) for antibody-directed enzyme
prodrug therapy (ADEPT). J. Med. Chem. 38, 5051-5065.
39. Blakey DC, Burke PJ, Davies DH, Dowell RI, East SJ,
Eckersley KP, et al. (1996) ZD2767, an improved system
for antibody-directed enzyme prodrug therapy that results in
tumor regressions in colorectal tumor xenografts. Cancer Res.
56, 3287-3292.
40. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone
LD, Sena L, et al. (2002) A phase I trial of antibody directed
enzyme prodrug therapy (ADEPT) in patients with advanced
colorectal carcinoma or other CEA producing tumors. Br. J.
Cancer 87, 600-607.
41. Neuberger MS, Williams GT, Fox RO. (1984) Recombinant
antibodies possessing novel effector functions. Nature 312,
604-608.
42. Bosslet K, Czech J, Hoffmann D. (1994) Tumor-selective
prodrug activation by fusion protein-mediated catalysis.
Cancer Res. 54, 2151-2159.
43. Chester K, Pedley B, Tolner B, Violet J, Mayer A, Sharma S,
et al. (2004) Engineering antibodies for clinical applications
in cancer. Tumor Biol. 25, 91-98.
44. Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW,
Read DA, et al. (2000) Catalytic activity of an in vivo tumor
targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
Int. J. Cancer 85, 571-577.
45. Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E,
Qureshi U, et al. (2005) Sustained tumor regression of human
colorectal cancer xenografts using a multifunctional manno-
sylated fusion protein in antibody-directed enzyme prodrug
therapy. Clin. Cancer Res. 11, 814-825.
46. Tolner B, Smith L, Begent RH, Chester KA. (2006) Production
of recombinant protein in Pichia pastoris by fermentation.
Nat. Protoc. 1, 1006-1021.
47. Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ,
Martin J, et al. (2006) A phase I study of single administration
of antibody-directed enzyme prodrug therapy with the recom-
binant anti-carcinoembryonic antigen antibody-enzyme fusion
protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin.
Cancer Res. 12, 6509-6516.
48. Wilkins D, Mayer A, Sharma S, Tolner B, Francis R, Springer
C, et al. (2008) Evidence of efficacy of antibody directed
enzyme prodrug therapy (ADEPT) in a Phase I trial in patients
with advanced carcinoma. AACR Meeting Abstracts, 2008,
LB-200.
Search WWH ::
Custom Search